Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: The mayo clinic experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 385-387

  Caudill, Jonathan S ^a   Brown, Paul D ^a,b   Cerhan, Jane H ^a   Rummans, Teresa A ^a  

^a MAYO CLINIC   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

citalopram; depression; glioblastoma multiforme; selective serotonin reuptake inhibitor; toxicity

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ADULT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OVERALL SURVIVAL; RADIATION DOSE; REVIEW; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961166457     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e8461a     Document Type: Review

References (10)

1. Litofsky NS, Farace E, Anderson F Jr, et al. Depression in patients with high-grade glioma: Results of the Glioma Outcomes Project. Neurosurgery. 2004;54:358 -366; discussion 366-357.
2. Steinbach JP, Blaicher HP, Herrlinger U, et al. Surviving glioblastoma for more than 5 years: The patient's perspective. Neurology. 2006;66:239-242. (Pubitemid 43970162)
3. Gathinji M, McGirt MJ, Attenello FJ, et al. Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol. 2009;71:299 -303; discussion 303.
4. Lazure KE, Lydiatt WM, Denman D, et al. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck. 2009;31:888-892.
5. Croyle RT, Rowland JH. Mood disorders and cancer: A National Cancer Institute perspective. Biol Psychiatry. 2003;54:191-194. (Pubitemid 37267849)
6. Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: The impact of the extent of resection on quality of life and survival. Neurosurgery. 2005;57: 495-504; discussion 495-504.
7. Parker NG, Brown CS. Citalopram in the treatment of depression. Ann Pharmacother. 2000;34:761-771. (Pubitemid 30395776)
8. Favale E, Audenino D, Cocito L, et al. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure. 2003;12:316-318. (Pubitemid 36806079)
9. Lydiatt WM, Denman D, McNeilly DP, et al. A randomized, placebocontrolled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134:528-535.
10. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557-564. (Pubitemid 40171237)